Why cannabis rescheduling is more than just a political game.

I understand the cynicism. The gears of government turn slowly, and when they do, the process can feel more like a calculated political dance than a genuine pursuit of progress. The back-and-forth on cannabis rescheduling from Schedule I to Schedule III has certainly tested our patience. But if we look beyond the political rhetoric and focus on the scientific and medical data, we can see a story of incredible progress that is too powerful to be stopped.

The fact is, a monumental shift has already occurred. The Department of Health and Human Services (HHS) has formally recommended that the DEA reschedule cannabis. This wasn't a political statement; it was the result of a comprehensive scientific and medical evaluation that concluded cannabis has accepted medical uses and a lower potential for abuse than Schedule I drugs. This is a scientific and public health win that transcends party lines and political cycles.

Here’s why I believe we have more reason for hope than ever before:

The Science Has Spoken, and It’s Undeniable.

For years, the federal government maintained the position that cannabis had "no currently accepted medical use." This claim flew in the face of what patients and researchers knew to be true. Now, we have official documentation from the HHS and FDA that validates what millions of people have experienced firsthand.

• Pain Management: A 2017 report from the National Academies of Sciences, Engineering, and Medicine found "conclusive or substantial evidence" that cannabis is effective for treating chronic pain in adults. This is a major finding, especially considering the ongoing opioid crisis.

• Nausea and Vomiting: There is also "conclusive evidence" that oral cannabinoids are effective in preventing and treating chemotherapy-induced nausea and vomiting. This provides real relief for cancer patients undergoing strenuous treatments.

• Multiple Sclerosis: For adults with multiple sclerosis (MS), short-term use of oral cannabinoids was found to improve patient-reported spasticity symptoms. This is a significant finding for a condition with limited treatment options.

These findings are not anecdotal; they are rooted in rigorous scientific evaluations. The DEA is legally bound to consider these scientific and medical determinations from the HHS, which means the conversation has fundamentally changed.

Public Opinion is Driving the Change.

The DEA received over 42,000 public comments on its initial proposal to reschedule. This is a testament to how deeply this issue resonates with the American people. The public is engaged, and the demand for a more rational approach to drug policy is overwhelming. As noted by the Drug Policy Alliance, nearly 70% of those comments supported federal decriminalization or legalization—a clear signal that the public wants even more than a move to Schedule III. This widespread public support puts sustained pressure on political leaders, regardless of who is in office.

The Economic and Research Benefits are Clear.

Rescheduling to Schedule III would be a game-changer for the cannabis industry. It would free state-legal cannabis businesses from the punitive federal tax code 280E, allowing them to reinvest billions of dollars into their businesses, employees, and communities. This move would also significantly ease restrictions on research, opening the door for more robust studies on cannabis's potential therapeutic applications, including for conditions like anxiety, PTSD, and epilepsy, where anecdotal evidence is strong but federal research has been limited.

While I remain a pragmatic observer of politics, I can’t ignore the overwhelming evidence and momentum. The scientific community has spoken, the public has spoken, and the economic benefits are undeniable. The political process may be slow and frustrating, but the foundation for change has been laid. We are no longer debating whether cannabis has medicinal value; we are simply waiting for the legal framework to catch up. And with science and public opinion on our side, it's not a question of if, but when.